Page last updated: 2024-09-03

2-chloro-n(6)cyclopentyladenosine and uric acid

2-chloro-n(6)cyclopentyladenosine has been researched along with uric acid in 1 studies

Compound Research Comparison

Studies
(2-chloro-n(6)cyclopentyladenosine)
Trials
(2-chloro-n(6)cyclopentyladenosine)
Recent Studies (post-2010)
(2-chloro-n(6)cyclopentyladenosine)
Studies
(uric acid)
Trials
(uric acid)
Recent Studies (post-2010) (uric acid)
25204327,9801,7179,982

Protein Interaction Comparison

ProteinTaxonomy2-chloro-n(6)cyclopentyladenosine (IC50)uric acid (IC50)
Solute carrier family 2, facilitated glucose transporter member 9Homo sapiens (human)300

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bardenheuer, HJ; Heller, AR; Koch, T; Plaschke, K; Rothermel, J; Schmeck, J; Weigand, MA; Wendel, M1

Other Studies

1 other study(ies) available for 2-chloro-n(6)cyclopentyladenosine and uric acid

ArticleYear
Adenosine A1 and A2 receptor agonists reduce endotoxin-induced cellular energy depletion and oedema formation in the lung.
    European journal of anaesthesiology, 2007, Volume: 24, Issue:3

    Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Adenosine Diphosphate; Adenosine Triphosphate; Analysis of Variance; Animals; Blood Pressure; Chromatography, High Pressure Liquid; Disease Models, Animal; Endotoxemia; Endotoxins; Energy Metabolism; Female; Lipopolysaccharides; Lung; Pulmonary Artery; Pulmonary Edema; Rabbits; Receptors, Purinergic P1; Respiratory Distress Syndrome; Time Factors; Uric Acid; Vasoconstriction

2007